140 related articles for article (PubMed ID: 17016655)
1. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells.
Eicke N; Günthert AR; Emons G; Gründker C
Int J Oncol; 2006 Nov; 29(5):1223-9. PubMed ID: 17016655
[TBL] [Abstract][Full Text] [Related]
2. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Gründker C; Völker P; Emons G
Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
[TBL] [Abstract][Full Text] [Related]
4. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
[TBL] [Abstract][Full Text] [Related]
5. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
Fister S; Günthert AR; Emons G; Gründker C
Cancer Res; 2007 Feb; 67(4):1750-6. PubMed ID: 17308117
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha.
Wu HM; Cheng JC; Wang HS; Huang HY; MacCalman CD; Leung PC
Cancer Res; 2009 May; 69(10):4202-8. PubMed ID: 19366794
[TBL] [Abstract][Full Text] [Related]
8. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
Gründker C; Emons G
Reprod Biol Endocrinol; 2003 Oct; 1():65. PubMed ID: 14594454
[TBL] [Abstract][Full Text] [Related]
9. Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.
Lee LT; Schally AV; Liebow C; Lee PP; Lee PH; Lee MT
Anticancer Res; 2008; 28(5A):2599-605. PubMed ID: 19035284
[TBL] [Abstract][Full Text] [Related]
10. Phosphatase and tensin homolog gene inhibits the effect induced by gonadotropin-releasing hormone subtypes in human endometrial carcinoma cells.
Zhao LJ; Liu N; Li XP; Wang JL; Wei LH
Chin Med J (Engl); 2010 May; 123(9):1170-5. PubMed ID: 20529558
[TBL] [Abstract][Full Text] [Related]
11. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
Günthert AR; Gründker C; Olota A; Läsche J; Eicke N; Emons G
Eur J Endocrinol; 2005 Oct; 153(4):613-25. PubMed ID: 16189183
[TBL] [Abstract][Full Text] [Related]
12. Effects of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) on endometrial cancer (HHUA) cell apoptosis and EGF stimulated cell proliferation in vitro.
Mochizuki T; Sakai K; Iwashita M
Growth Horm IGF Res; 2006 Jun; 16(3):202-10. PubMed ID: 16844395
[TBL] [Abstract][Full Text] [Related]
13. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9.
Cheung LW; Leung PC; Wong AS
Cancer Res; 2006 Nov; 66(22):10902-10. PubMed ID: 17108127
[TBL] [Abstract][Full Text] [Related]
15. Proliferative signal transduction by epidermal growth factor (EGF) in the human salivary gland adenocarcinoma (HSG) cell line.
Sato N; Kyakumoto S; Sawano K; Ota M
Biochem Mol Biol Int; 1996 Mar; 38(3):597-606. PubMed ID: 8829620
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the antiproliferative effect of TGFbeta by EGF in primary human ovarian cancer cells.
Dunfield LD; Nachtigal MW
Oncogene; 2003 Jul; 22(30):4745-51. PubMed ID: 12879019
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation.
Qiu L; Zhou C; Sun Y; Di W; Scheffler E; Healey S; Kouttab N; Chu W; Wan Y
Int J Oncol; 2006 Oct; 29(4):1003-11. PubMed ID: 16964397
[TBL] [Abstract][Full Text] [Related]
18. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.
Gründker C; Günthert AR; Millar RP; Emons G
J Clin Endocrinol Metab; 2002 Mar; 87(3):1427-30. PubMed ID: 11889221
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor activates protein kinase C in the human endometrial cancer cell line HEC-1-A.
Connor P; Talavera F; Kang JS; Burke J; Roberts J; Menon KM
Gynecol Oncol; 1997 Oct; 67(1):46-50. PubMed ID: 9345355
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor in cultured human retinal pigment epithelial cells.
Yan F; Hui YN; Li YJ; Guo CM; Meng H
Ophthalmologica; 2007; 221(4):244-50. PubMed ID: 17579290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
